Evolus, Inc. (NASDAQ:EOLS) Q2 2025 Earnings Call Transcript
Operator: Good afternoon, everyone, and thank you for standing by. Welcome to Evolus' Second Quarter Earnings Conference Call.
Evolus Inc. (EOLS)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Tang Capital Management Kevin C. Tang | 4,997,399 | $46,026,045 | 2.33% | |
| 2. | Nantahala Capital Management Wilmot B. Harkey And Daniel Mack | 4,197,926 | $38,662,898 | +15% | 1.51% |
| 3. | Caligan Partners David Johnson | 3,341,970 | $30,779,544 | +23% | 5.92% |
| 4. | Perceptive Advisors Joseph Edelman | 2,474,843 | $22,793,304 | -41% | 0.85% |
| 5. | Soleus Capital Guy Levy | 2,119,000 | $19,515,990 | +97% | 1.29% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $9.45 | 20,000 | $189,000.00 | 50,378 | 2025-06-09 | Filing | |
| $7.41 | 174,967 | $1,296,505.47 | 275,550 | 2023-08-15 | Filing | |
| $11.11 | 14,043 | $156,064.07 | 7,296,543 | 2021-08-13 | Filing | |
| $10.99 | 23,000 | $252,774.60 | 7,282,500 | 2021-08-12 | Filing | |
| $10.78 | 1,091 | $11,755.53 | 10,000 | 2022-09-12 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $9.89 | 16,582 | $164,054.02 | 364,927 | 2025-06-16 | Filing | |
| $10.05 | 111,323 | $1,119,141.25 | 381,509 | 2025-06-13 | Filing | |
| $9.87 | 3,385 | $33,396.75 | 359,082 | 2025-05-12 | Filing | |
| $10.02 | 6,494 | $65,069.88 | 167,089 | 2025-05-13 | Filing | |
| $9.87 | 15,787 | $155,756.12 | 492,832 | 2025-05-12 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,184,056 | $38,535,155 | 0% | |
| 2. | 3,318,250 | $30,561,083 | 0% | |
| 3. | 2,435,550 | $22,431,416 | 0.9% | |
| 4. | 1,664,828 | $15,333,066 | 0.14% | |
| 5. | 1,406,594 | $12,954,731 | 0% |
News See All
Evolus, Inc. (EOLS): A Bull Case Theory
We came across a bullish thesis on Evolus, Inc. (EOLS) on Substack by Greg ┃The Elevator Pitch. In this article, we will summarize the bulls’ thesis on EOLS. Evolus, Inc.
Evolus, Inc. (NASDAQ:EOLS) Q1 2025 Earnings Call Transcript
Operator: Good afternoon, everyone. And thank you for standing by. Welcome to Evolus's First Quarter Earnings Conference Call. As a reminder, today's conference is being recorded and webcast live.
Evolus, Inc. (NASDAQ:EOLS) Q4 2024 Earnings Call Transcript
Operator: Good afternoon, everyone, and thank you for standing by. Welcome to Evolus Fourth Quarter and Full Year 2024 Earnings Conference Call.
12 Best Small Cap Pharma Stocks to Buy Now
Emily Field, Head of European Pharma Research at Barclays, spoke on CNBC on February 20 about the performance of obesity medications, the effects of US tariffs, and the dynamics of the pharmaceutical ...
Evolus, Inc. (NASDAQ:EOLS) Q3 2024 Earnings Call Transcript
Operator: Good afternoon, everyone, and thank you for standing by. Welcome to Evolus Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Top 10 Holdings of Caligan Partners
Founded in 2017, Caligan Partners is one of the most significant specialty hedge funds.
Evolus, Inc. (NASDAQ:EOLS) Q2 2024 Earnings Call Transcript
Operator: Good afternoon, everyone and thank you for standing by. Welcome to Evolus' Second Quarter 2024 Earnings Conference Call. As a reminder, today's conference is being recorded and webcast live.
Evolus, Inc. (NASDAQ:EOLS) Q1 2024 Earnings Call Transcript
Evolus, Inc. misses on earnings expectations. Reported EPS is $-0.22295 EPS, expectations were $-0.07.
11 Best Low Price Pharma Stocks To Invest In
In this piece, we will take a look at the 13 best low price pharma stocks to invest in.